A sto­ried Chi­nese phar­ma part­ner of Bris­tol My­ers, Am­gen — and avid biotech sup­port­er — plots HK IPO

A hefty phar­ma IPO is com­ing to Hong Kong.

Sim­cere isn’t one of the group of pre-rev­enue biotechs tak­ing ad­van­tage of Hong Kong’s 2-year-old new rules that opened up the stock ex­change. A clos­er coun­ter­part would be Han­soh, which reaped a $1 bil­lion wind­fall from its HKEX de­but a year ago: a sto­ried pow­er­house com­pa­ny that bags siz­able rev­enue from a slate of old­er gener­ic drugs. (Co­in­ci­den­tal­ly, both com­pa­nies have head­quar­ters in the province of Jiang­su.)

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER